Litcius/Paper detail

Napabucasin Plus FOLFIRI in Patients With Previously Treated Metastatic Colorectal Cancer: Results From the Open-Label, Randomized Phase III CanStem303C Study

Manish A. Shah, Takayuki Yoshino, Niall C. Tebbutt, Axel Grothey, Josep Tabernero, Rui‐Hua Xu, Andrés Cervantes, Sang Cheul Oh, Kensei Yamaguchi, Marwan Fakih, Alfredo Falcone, Christina Wu, Vi K. Chiu, Jiří Tomášek, Johanna C. Bendell, Marilyn Fontaine, Matthew Hitron, Bo Xu, Julien Taı̈eb, Eric Van Cutsem

2022Clinical Colorectal Cancer30 citationsDOI

Topics & Concepts

MedicineColorectal cancerPopulationInternal medicineOxaliplatinFOLFIRIBiomarkerCancerOncologyGastroenterologyPharmacologyEnvironmental healthChemistryBiochemistryBioactive Compounds and Antitumor AgentsCancer Mechanisms and TherapySirtuins and Resveratrol in Medicine
Napabucasin Plus FOLFIRI in Patients With Previously Treated Metastatic Colorectal Cancer: Results From the Open-Label, Randomized Phase III CanStem303C Study | Litcius